Gambichler, Thilo
Majchrzak-Stiller, Britta
Peters, Ilka
Becker, Jürgen C.
Strotmann, Johanna
Abu Rached, Nessr
Müller, Thomas
Uhl, Waldemar
Buchholz, Marie
Braumann, Chris
Funding for this research was provided by:
Katholisches Klinikum Bochum gGmbh
Article History
Received: 30 April 2023
Accepted: 1 June 2023
First Online: 14 June 2023
Declarations
:
: T.G. has received speakers and/or advisory board honoraria from BMS, Sanofi-Genzyme, MSD, Novartis Pharma, Roche, Abbvie, Almirall, Janssen, Lilly, Pfizer, Pierre Fabre, Merck-Serono, outside of the submitted work. T.M. is employed by Geistlich Pharma AG, Wolhusen, Switzerland. J.C.B. is receiving speaker’s bureau honoraria from Amgen, Pfizer, Merck-Serono and Sanofi and is a paid consultant/advisory board member for eTheRNA, Merck-Serono, Pfizer, 4SC and Sanofi. His group receives research grants from BMS, Merck-Serono, and Alcedis. All other authors declare no competing interests. The funders of this study had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
: Not applicable.
: Not applicable.